Cell Therapy Next Current Issue

The following articles appeared in the print edition of Cell Therapy Next.

Table of Contents

• Navigating the journey to develop safer CARs Drew Amorosi
• CAR-T, baseline risk factors confer elevated rate of major adverse CV events Scott Buzby
• FDA clears IND for natural killer T-cell therapy to treat COVID-19
• FDA clears IND application for CAR T-cell therapy targeting gastric, pancreatic cancers
• FDA clears IND application for ’dual-switch’ CAR-T for HER2-positive tumors
• FDA extends action date for Bristol-Myers Squibb’s CAR-T for advanced large B-cell lymphoma
• FDA delays application for investigational CAR-T for advanced multiple myeloma
• Discovery of cell surface protein may lead to CAR-T for inflammatory diseases Drew Amorosi
• Exploring alternatives to CAR T-cell therapy Drew Amorosi
• FDA grants fast track designation to vaccine-enhanced cell therapy for glioblastoma
• Real-world CAR T-cell therapy as safe, effective as in clinical trial setting Drew Amorosi
• CAR-T shows ‘significant survival benefit’ vs. standard of care in lymphoma subset Drew Amorosi
• Gene therapy appears to reduce sickle cell disease-related complications Drew Amorosi
• Orvacabtagene autoleucel CAR-T shows ‘promising efficacy’ for advanced multiple myeloma Drew Amorosi
• Tumor-infiltrating lymphocytes show ‘remarkable’ results in advanced melanoma Drew Amorosi
• NIH awards grant to UCLA to develop CAR T-cell therapies for HIV Drew Amorosi
• Phase 2 trial to assess natural killer cell therapy regimen for advanced pancreatic cancer Drew Amorosi